About the Authors

Yann Gibert

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

Victoria J. Lattanzi

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

Aileen W. Zhen

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

Lea Vedder

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

Frédéric Brunet

Affiliation Institut de Génomique Fonctionnelle de Lyon, Ecole Normale Supérieure, Lyon, France

Sarah A. Faasse

Affiliation Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

Jodie L. Babitt

Affiliation Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

Herbert Y. Lin

Affiliation Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

Matthias Hammerschmidt

Affiliation Institute for Developmental Biology, University of Cologne, Koeln, Germany

Paula G. Fraenkel

pfraenke@bidmc.harvard.edu

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

Competing Interests

H.Y.L. and J.L.B. have ownership interest in a start-up company Ferrumax Pharmaceuticals, which has licensed technology from the Massachusetts General Hospital.

Author Contributions

Conceived and designed the experiments: YG PF. Performed the experiments: YG VJL AWZ LV SF PF. Analyzed the data: YG FGB PF. Contributed reagents/materials/analysis tools: JB HL MH PF. Wrote the paper: PF.